The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) and its clinical
manifestation, the coronavirus disease 2019 (COVID19) have rapidly spread across the …

Patients with lymphoma, especially those treated with anti-CD20 monoclonal antibodies,
suffer high COVID-19-associated morbidity and mortality. The goal of this study was to …

Some viruses are known to be associated with the onset of specific cancers. These
microorganisms, oncogenic viruses or oncoviruses, can convert normal cells into cancer …

The severe acute respiratory syndrome associated coronavirus‑2 (SARS‑CoV‑2) poses a
threat to human life worldwide. Since early March, 2020, coronavirus disease 2019 (COVID …

Background The COVID-19 has caused significant mortality and morbidity across the globe.
Patients with cancer are especially vulnerable given their immunocompromised state. We …

Introduction Coronavirus disease 2019 resulted in a 30% mortality rate in patients with
thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute …

Purpose There are limited data on SARS-CoV-2 (COVID-19) infection in children with
cancer or after haematopoietic stem cell transplant (HSCT). We describe the severity and …

Cancer patients are susceptible to severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2). Different antitumor treatments have attracted wide attention in the context of …

Patients with multiple myeloma have a compromised immune system, due to both the
disease and antimyeloma therapies, and may therefore be particularly susceptible to COVID …

Aim Patients with cancer are at an increased risk for severe coronavirus disease of 2019,
thus data on the safety and efficacy of severe acute respiratory syndrome coronavirus-2 …